Adnexus Therapeutics

Acquired

Pioneering Adnectin therapeutics based on human fibronectin.

Waltham, United States · Founded 2003 · $42.5M raised

Employees
1–10
Founded
2003
Business Model
B2B
Total Funding
$42.5M
Last Round
$15.5M Series CAug 2007
Rounds
2
Acquired by
Bristol-Myers Squibb CompanySep 2007 · $430.0M

About

Adnexus Therapeutics, founded in 2003 and headquartered in Waltham, Massachusetts, was a biopharmaceutical company that pioneered Adnectin therapeutics — engineered variants of the tenth type III domain of human fibronectin. Adnectins were designed as a new protein scaffold platform to generate highly potent, specific, and stable therapeutic agents with favorable half-life and high-yield E. coli production. The company's lead oncology compound, CT-322, was an Adnectin inhibitor of vascular endothelial growth factor receptor-2 (VEGFR-2) developed as an anti-angiogenic cancer therapy. Adnexus was founded by Flagship Pioneering (then Flagship Ventures) and acquired by Bristol-Myers Squibb in September 2007 for approximately $430 million, making it one of the largest biotech acquisitions of that year.

Summary

Adnexus Therapeutics is a Biotech company based in Waltham, United States, founded in 2003. It has raised $42.5M in total across 2 rounds, most recently a $15.5M Series C round in Aug 2007. Investors include Bristol Myers Squibb, HBM BioVentures and Venrock.

Funding History

AcquisitionAcquisition by Bristol-Myers SquibbSep 2007

Sign up to see all 3 rounds

Series B through Acquisition — per-round amounts, valuations, and who invested in each round.

Investors

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Adnexus Therapeutics on Indexed.vc
<a href="https://indexed.vc/companies/adnexus-therapeutics"><img src="https://indexed.vc/api/badge/company/adnexus-therapeutics" alt="Adnexus Therapeutics on Indexed.vc" width="260" height="76" /></a>